chrisvoncsefalvay/vaers-outcomes huggingface dataset:
On April 16th started to have a low grade fever, had a horrible cough the fever went away a day after that. His coughing got worst and he went to his doctor stated it was a bad sinus infection. Went to an urgent care was diagnosed with pneumonia and they gave him antibiotics. Two weeks later his pneumonia came back. Eight weeks after the shot he went to his cardiologist and they told him it was because of the shot.
I HAD PAIN AT SITE, CHILLS, HEADACHE AND BODY PAINS THE DAY AFTER THE SHOT.  TREATED WITH TYLENOL.   ON DAY 4 I GOT A TERRIBLE METALLIC FOUL TASTE THAT I AM STILL DEALING WITH. ALSO HAD HEART PALPATATIONS AND DIZZY QUEAZY FEELING. THE HEART PALPATATIONS ARE NOW LESS BUT THE TASTE DISORDER IS STILL THERE.  WILL IT GO AWAY? MY WORK REQUIRES THAT I CAN TASTE.
Information has been received from a pharmacist concerning a 68 year old female with thyroid disorder, no drug reaction or allergies who on 11-FEB-2008 was vaccinated subcutaneously into the right arm with Zostavax (Oka/Merck) 658862/1415U. Concomitant therapy included levothyroxine Na and vitamins (unspecified). On 12-FEB-2008 the patient developed injection site swelling and redness. The patient presented to the pharmacy on 13 FEB 2008 with a red swollen broad rash that was warm to touch at the injection site. The pharmacist did not identify the rash as either chicken pox or zoster. At the time of reporting the patient had not yet recovered. Unspecified medical attention was sought. There were no lab diagnostic studies performed. There was no product quality complaint. Additional information has been requested.
On June 07, 2022 I woke up with a sore throat, I was warmer than usual. I took a home COVID 19 test. The second day I started coughing and had some phlegm, my temperature was elevated for three days. By day three the cough went away, no more aches or pains it felt like a light cold or flu. I had received a prescription of Paxlovid on June 8, 2022. By June 12, 2022 I was testing negative and feeling much better.
Patient is a 13 years old boy and he is going through behavioral changes since he received his Pfizer covid19 vaccine. Adverse events since he received the Pfizer covid19 vaccine are sudden weight loss about ~12lbs, random giggling, self-talking non-stop 24/7, not sleeping at all, getting angry and violent, lost focus and attention and not even able to action on one step instructions at school and at home. It's been almost 2weeks since he attended regular school due to his current health condition. I want to talk to someone immediately and discuss about my son's health situation. Please call me. Thank you.
The pt came in to let me know that she had gone to her doctor due to swelling and redness on arm where she recieved the injection and the doctor diagnosed her with cellulitus. I called the doctor office to confirm diagnosis.
The pt experienced a 2" diameter area of erythema with tenderness to the touch, and itchiness. Symptoms much better 24 hours later. Completely resolved by 6/3/00.
Patient felt very tired, weak, extreme fatigue, needs assistance for her normal daily function and body pain for 1 day and the weakness feeling for 2 day.
Gave a VARIVAX to a 6 month old. Only indicated for 12 months and older.
It was reported that a 3 month old female infant received a Tripedia, a Prevnar, a Hib-Titer and an IPOL vaccination on 2/28/01 at 18:00 PM. At 18:03 PM, this pt was limp, hyporesponsive, pale and lethargic. She was crying, intermittently, to stimulation but persistent stimulation for 5-10 minutes, brought her out of that state. Paramedics came, pt went to ER and was discharged. From additional correspondence received on 4/19/01, it was reported, "Reviewed, no additional information at this time". This case is closed.
Pt recvd MMR during pregnancy; baby born @ term 10SEP91 w/low-set lt ear;
pt exp profuse sweating, lethargy, mid low grade h/a, anorexia, intermittent fever, chills, malaise;seen by MD;ESR 86, WBC 15;UA ketones & 1+ w/0 to 1 RBC;dx viral illness poss viral hepatitis;final dx staph liver abscess;rxn not r/t vax
unusual, high pitched cry x 1 1/2 hr 2-3 hrs p/given DTP;
Developed a skin rash on pubic area, belly, wait, around arm pits and back; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Developed a skin rash on pubic area, belly, wait, around arm pits and back) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047A21A) for COVID-19 vaccination.     No Medical History Information was reported.     On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH (Developed a skin rash on pubic area, belly, wait, around arm pits and back). At the time of the report, RASH (Developed a skin rash on pubic area, belly, wait, around arm pits and back) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 25-Mar-2021 and was forwarded to Moderna on 25-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of RASH (Developed a skin rash on pubic area, belly, wait, around arm pits and back) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047A21A) for COVID-19 vaccination.     No Medical History Information was reported.     On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH (Developed a skin rash on pubic area, belly, wait, around arm pits and back). At the time of the report, RASH (Developed a skin rash on pubic area, belly, wait, around arm pits and back) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided.
This case was reported by a consumer via call center representative and described the occurrence of feeling hot in a 72-year-old female patient who received SHINGRIX for prophylaxis. Previously administered products included SHINGRIX with an associated reaction of headache (receive 1st dose on 30th August 2018 and experienced severe headache, difficulty sleeping, tiredness and pain, refer case US2019004237). On 4th January 2019, the patient received the 2nd dose of SHINGRIX (intramuscular). On 4th January 2019, less than a day after receiving SHINGRIX, the patient experienced feeling hot and chills. On 6th January 2019, the outcome of the feeling hot and chills were recovered/resolved. It was unknown if the reporter considered the feeling hot and chills to be related to SHINGRIX. Additional details were provided as follows: The patient reported that she experienced side effects to the SHINGRIX after each injection. The patient reported that she received 2nd dose of SHINGRIX and experienced feeling hot and chills and the issues lasted for two days. The reporter gave consent to follow up.
Pt reports facial numbness 2 days after vaccine admin. On exam (11/8/10), pt with Bell's Palsy, no other sx.
2nd dosage administered on 01/25/2021 @ 9:15am   DAY 1 (01/25/2021) ? Diarrhea (within 3 hours) ? Headache (began midafternoon) ? Extremely fatigue, tiredness ? Low grade fever 100.4  DAY 2 (01/26/2021) ? Sudden light headedness, dizziness  ? Continued fatigue, tiredness ? Some nausea
Painful axillary adenopathy, with associated soft tissue swelling. From the mid-axillary line down, there is a tennis-ball size swelling that is painful and worsening.
This case was reported by a pharmacist via call center representative and described the occurrence of blister in a 60-year-old female patient who received SHINGRIX (batch number D294J, expiry date 22nd March 2021) for prophylaxis. On 31st January 2019, the patient received SHINGRIX. On an unknown date, less than a week after receiving SHINGRIX, the patient experienced blister and lip blister. On an unknown date, the outcome of the blister and lip blister were not recovered/not resolved. It was unknown if the reporter considered the blister and lip blister to be related to SHINGRIX. Additional details were provided as follows: The patient experienced blisters across her upper lip and in her nostril. At the time of reporting the patient still had the symptoms. This case was linked with case US2019020317, reported by the same reporter.
Patient presented for second COVID vaccine (1st dose given 1/21/21).  While in observation, patient started feeling chest & throat tightness. Nurse in observation reports pt looked anxious. EMS was called over. EMS assessed patient and advised transfer to emergency department. Patient was taken to ER. At the ER, patient was diagnosed with chest tightness and shortness of breath. He received 325 mg of aspirin.  EKG showed rate 63, no ST-T changes, no ectopy, normal PR & QRS intervals with rhythm atrial fibrillation. No epinephrine was given in the field (at vaccination site) or while in the ER.  Patient was in NSR at time of discharge with recommendation for close cardiac follow up.
Information has been received from a lawyer regarding a case in litigation concerning a female patient (age unknown). The patient's medical history, concurrent conditions and concomitant medication use were not provided. On or about 22-FEB-2016, the patient was vaccinated with ZOSTAVAX, (lot# and route unknown) as recommended for routine adult health maintenance and for the prevention of shingles.  The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster.  On or about 26-MAY-2016, the patient was treated at a medical center for a severe vesicular outbreak, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
Approximately 2-3 weeks after my 4th dose vaccination I contracted COVID-19 and experienced the following symptoms: fatigue, mild fever (99.7), body aches, headache, runny nose, sore throat and cough. i took ibuprofen and had a virtual visit with my nurse practitioner and was prescribed with Paxlovid and was taking it 2x a day for 5 days and my symptoms started improving each day when I was taking it.
Adverse event: Day after vaccination, experienced severe dizziness, nausea, and fever. Fell over and experienced loss of vision and loss of control of limbs, difficulty talking. Loss of normal color in skin, instead had greyish/blue tint.  Treatment: Cold compress, juice, rest laying down Outcomes: After 10 min of having a cold compress and juice, regained vision and ability to talk. 30 min later, regained ability to move limbs. Still could not stand up without falling over for a couple hours. After 6 hrs, only remaining symptoms were slight fever, fatigue, and some dizziness. After 2 days experiencing fatigue, headache, and dizziness, returned to normal health.
Evening after the vaccination, Patient experienced redness, soreness, and inflammation radiating from the injection site downward to the elbow. Morning after the vaccination patient experienced a hive at the injection site. Soreness continued until Friday following the vaccination (approx. 4 days).
Pt says that his main problem since shot #3 is his short term memory loss. Pt states that he can't remember a phone number that he frequently calls. He has a constant feeling of exhaustion. At least once a week he experiences sharp pains in his legs and arms as if he pinched a nerve. This pain lasts for at least one minute.
Post vaccination; patient seen unconscious on the floor for 30 seconds. Vitals taken at 1105am Pulse 59 BP 109/67 RESP 19. At 1120am reassessed Pulse 84 BP 111/74 RESP 18. Patient is stable and released from the facility accompanied by friend
Pt recv vax on 8/3/98; on same day pt exp striking scream at night >16 days & severe agitation in wake to sleep cycle.  Pt hosp; dx=encephalitis; pt imp 9/11/98.  As of 9/28/98 pt recovered.
Initial report was received from a consumer on 24 January 2008.  A five-year-old male child with a history of peanut allergies, had received an intramuscular right deltoid injection of TRIPEDIA (lot number not reported) and an intramuscular left deltoid injection of IPOL (lot number not reported) on 22 January 2008 and 24 hours later, he developed right arm swelling, redness and itching from the shoulder to the elbow.  Corrective treatments included TYLENOL.  At the time of the report, the patient had been scheduled to follow-up with their pediatrician and had not yet recovered from the event.
The patient was given a booster dose of primary pfizer vaccine when they were expectiong a booster dose of pfizer bivalent vaccine.  The patient was called three times and three messages were left to contact us so that we could inform them of the error.  There was no response to these attempts.
Constant headache that still persists. Bruises. Severe knee pain. Mild rash on the face. Pain in the area of the vaccine with swollen lymph nodes. Fever for the first three days with muscle aches including back.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. Pharmacist reported that on 23-JAN-2013 the patient received the first dose of PNEUMOVAX 23 (lot number, dose, indication and route were not reported), and another dose of PNEUMOVAX 23 (lot number, dose, indication and route were not reported), on 22-OCT-2013. Concomitant medications were not reported. No adverse effects reported. Additional information has been requested.
Moderna Bivalent vaccine be given as a Primary dose; No adverse event; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Moderna Bivalent vaccine be given as a Primary dose) and NO ADVERSE EVENT (No adverse event) in an 18-year-old patient of an unknown gender who received mRNA-1273 BIVALENT (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS1744B) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 BIVALENT (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Moderna Bivalent vaccine be given as a Primary dose) and NO ADVERSE EVENT (No adverse event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Moderna Bivalent vaccine be given as a Primary dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.            No concomitant medications were reported. The expiration date of vaccine was 12-MAR-2023. No treatment medications were reported.
10 minutes after vaccines given, patient felt nausea and itchy all over. No visible rash was seen. I told patient to stay in store so I could administer BENADRYL, but she insisted on going home. When she was home she took BENADRYL and it helped.
This case was reported by a consumer and described the occurrence of influenza-like symptoms in an unspecified number of adult patients who received SHINGRIX. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced influenza-like symptoms. On an unknown date, the outcome of the influenza-like symptoms was unknown. It was unknown if the reporter considered the influenza-like symptoms to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not applicable for this report. An unspecified number of patients experienced flu-like symptoms. The reporter stated the SHINGRIX vaccination was beyond worth to be protected from the shingles. The reporter could not be contacted. This case is 1 of 4 cases, reported by the same reporter.
pt recv vax & devel inj site rxn characterized by redness & swelling w/pain radiating from site down the arm;pt has recv pneumococcal vax in the past;this is one of ten patients who exp above rxn p/vax;
later she had pain under her left breast; This is a spontaneous report from a contactable consumer. A 78-year-old female patient received 1st dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) at single dose on 13Apr2021 via an unknown route in left deltoid for Covid-19 immunization. Medical history and concomitant drug were not provided. She received the vaccine in the left deltoid, later she had pain under her left breast similar to where an underwire bra would be.  The symptoms lasted for about 2 days but was only a little painful on 15Apr2021 morning. Outcome of the event was resolving.   No follow-up attempts are needed. No further information is expected.
Received 1st dose at approx 12:33 PM 15 minutes obs ended at 12:48 PM with no concerns on drive home, at approx 1:00 PM, began to feel as if my lower lip was swelling, mandible was numb, throat felt like something was stuck in it at 1:03 PM called 911 for assistance squad responded - I was hypertensive, tachycardic, and RR was in the 30's. Felt dizzy, numbness and tingling in mandible, elbows to finger tips. Did not require oxygenation or epi Transported to hospital, observed for approx 4 hrs. Recevied PO prednisone, benadryl, and ativan. Discharged home same day. Next day with intermittent chills,
Client reports she had near syncope episode. At 12:00 PM, Client reported episode to co-worker and was transported via ambulance to ED. IV fluids administered. No medications. Client released to home within a few hours.
they have pain; after their second dose of the Moderna covid19 vaccine their arm was swollen real bad/ left arm was extremely swollen; left arm was extremely swollen and sore and red.; left arm was extremely swollen and sore and red.; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (they have pain), VACCINATION SITE SWELLING (after their second dose of the Moderna covid19 vaccine their arm was swollen real bad/ left arm was extremely swollen), VACCINATION SITE ERYTHEMA (left arm was extremely swollen and sore and red.) and VACCINATION SITE PAIN (left arm was extremely swollen and sore and red.) in an 88-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     The patient's past medical history included Pneumonia and Tetanus. Concurrent medical conditions included Allergy NOS (could not remember to what was allergy to).    In June 2022, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN (they have pain), VACCINATION SITE SWELLING (after their second dose of the Moderna covid19 vaccine their arm was swollen real bad/ left arm was extremely swollen), VACCINATION SITE ERYTHEMA (left arm was extremely swollen and sore and red.) and VACCINATION SITE PAIN (left arm was extremely swollen and sore and red.). At the time of the report, PAIN (they have pain), VACCINATION SITE SWELLING (after their second dose of the Moderna covid19 vaccine their arm was swollen real bad/ left arm was extremely swollen), VACCINATION SITE ERYTHEMA (left arm was extremely swollen and sore and red.) and VACCINATION SITE PAIN (left arm was extremely swollen and sore and red.) had resolved.            Patient never had Covid-19 or tested. No concomitant medications was reported. No treatment medications was reported.
Patient reported numbness in her arm radiating to her neck, jaw and tongue aprox. 5 min after shot. sated she had no feeling.   Duration of numbness lasted 15 minutes.   Administer 50mg  Benadryl po x1  Observed patient. no swelling of tongue, larynx or lymph area. At 30 minutes patient reported sx had gone away. advised patient that if returned that immediate medical treatment must be obtained and to go to ed.
Information has been received from a registered nurse (school nurse) concerning a child between the ages of 6 and 11 years old who on 20-JUN-2002, was vaccinated with a dose of varicella virus vaccine live (Oka/Merck). On approximately 03-DEC-2007 the patient was experiencing chickenpox. It was not specified how may doses of varicella virus vaccine live (Oka/Merck) the patient received. Medical attention was sought via an office visit with the physician. At the time of the report the patient was recovering. There was no product quality complaint involved. No further information was provided. Additional information has been requested. This is one of several reports from the same source.
Received Moderna COVID-19 vaccine on 01/14/2021. Called on 01/22/2021 to report redness and itching to vaccine site which patient noticed on 01/21/2021.
Vaccinations site (left arm) - I received two vaccinations. 1) yearly flu 2) pneumonia. Arm became badly swollen, hot and painful to touch, high fever, chills, pain throughout my body-This cont'd for 48 hours - 2nd nite my ned was soaked w/sweat. Extremely ill, almost dialed 911. couldnt eat for 3 days-knot in my arm for a month. Still sore a month after injections/Ibuprofen for fever and pain.
Rigidity 4 limbs, eyes rolled back in head; abn breathing, loss of consciousness, lasted 3-4 mins, post ictal drowsiness afterwards (72 hrs p/immun); no treatment given;
Patient recieved his immunization and after walking from the immunization area to the seated waiting area, he suddently lost consciousness and fell to the floor from standing . Upon falling, his face and jaw line were the first part of his body to make contact with the ground. Immdiate examiation post-fall was completed to ensure his spinal column was un-harmed prior to lifting him to a sitting position. He became nauseated, along with amnesia and EMS was immediately called to the scene for further evaluation and to take him to a hospital for routine testing.
Chronic diarrhea, chronic itchiness- eczema worsened, wheat sensitivities, bile in stool, worsening of gallbladder symptoms
c/o tingling in nose/throat, dizziness, Chills administered 25mg Benedryl PO @ 1225 v/s 98% RA HR 81 126/82 c/o Cough and itching of throat @ 1246 93% RA, 124/84, HR 83 c/o Tightness in R/chest, symmetrical chest, diminished throughout, with wheezes and faint crackes on RUL clears with cough. 1306 1306 called EMS - sent to ER for Eval
A physician reported that a child received an injection of Prevnar. On 6/8/00, the child developed swelling at the injection site, extending to involve the entire arm. The child was treated with steroids.
Pt states 3 hrs after getting HPV shot, got sore throat, blotchy rash which largely resolved by 11/29/11.
Initial and follow up information has been received from a physician's assistant for the Pregnancy Registry for GARDASIL concerning a 14 year old female with no known allergies and attention deficit/hyperactivity disorder who on 15-FEB-2007 was vaccinated with GARDASIL (Lot#655165/1425F).  Concomitant therapy included CONCERTA.  On 15-MAR-2007, a urine pregnancy test revealed the patient was pregnant (LMP & EDD = approximately 28-JAN-2007 & 04-Nov-2007).  On 17-MAR-2007, a quantitative HCG showed 6-7 weeks gestation.  The patient had no symptoms and sought unspecified medical attention.  On 01-JUL-2008 the physician's assistant (PA) was informed by the patient's sister, that the patient delivered a stillborn baby "early."  The PA was given very limited information and did not know the date of delivery or estimated gestational age.  No further information is available.
vomiting, pruritus, rash-arms, neck, face (red, blotchy), sleepy, inc fever next day;